How Safe Is AbbVie, Inc.'s Dividend Now?

AbbVie gave its payout a mighty boost just ahead of a major trial failure. Maybe now's a good time to look under the hood.

AbbVie Inc.'s (NYSE:ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs.

At recent prices, AbbVie shares offer a nice 4% yield. That's more than twice as much as you'll get from the average dividend-paying stock in the benchmark S&P 500 index. If you're a cautious investor worried about a dividend that looks too good to be true, here's what you need to know about the pillars supporting AbbVie's rapidly rising payouts.

In case you interested of stock analysis of other bloggers, click on link below:

Analysis Collection

No comments:

Post a Comment